Kiora Pharmaceuticals Inc
KPRX | $0.502 -1.57% -1.59% 49K
|
Manufacturing
(0.0% 1d) (-15.9% 1m) (-85.5% 1y) (0.0% 2d) (0.0% 3d) (-8.9% 7d) (29.66% volume)
Earnings Calendar: 2024-03-25
Market Cap: $ 13,180,611
https://eyegatepharma.com
Sec Filling | Patents | 14 employees
(United States) EyeGate Pharmaceuticals Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate's lead product, Ocular Bandage Gel ('OBG'), is based on a modified form of the natural polymer hyaluronic acid. The objective of OBG is to protect the ocular surface in order for the body to re-epithelialize the cornea and improve ocular surface integrity. The product is applied as a clear topical gel, to the damaged ocular surface, and possesses unique properties that help hydrate and protect the ocular surface to allow for wound healing. EyeGate is in clinical evaluation for two different patient populations: (1) patients undergoing photorefractive keratectomy ('PRK') surgery to demonstrate corneal wound repair after refractive surgery; and (2) patients with punctate epitheliopathies ('PE') as a result of dry eye to promote reduction of PEs.
msa
add to watch list Paper trade email alert is off
Press-releases
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
Published: 2024-04-11 (Crawled : 17:00) - biospace.com/
KPRX | $0.502 -1.57% -1.59% 49K
|
Manufacturing
|
| O: 3.23%
H: 0.16%
C: -1.79%
granted approval pharmaceuticals research for grant trial foundation study
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
Published: 2024-04-05 (Crawled : 14:30) - biospace.com/
KPRX | $0.502 -1.57% -1.59% 49K
|
Manufacturing
|
| O: -1.89%
H: 4.91%
C: 4.91%
pharmaceuticals
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Published: 2024-03-28 (Crawled : 16:00) - biospace.com/
KPRX | $0.502 -1.57% -1.59% 49K
|
Manufacturing
|
| O: -2.26%
H: 20.0%
C: 17.67%
pharmaceuticals meeting trial
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases
Published: 2024-03-25 (Crawled : 15:30) - biospace.com/
KPRX | $0.502 -1.57% -1.59% 49K
|
Manufacturing
|
| O: 0.32%
H: 0.0%
C: -3.46%
rare pipeline pharmaceuticals
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye
Published: 2024-03-08 (Crawled : 14:30) - biospace.com/
KPRX | $0.502 -1.57% -1.59% 49K
|
Manufacturing
|
| O: 2.4%
H: 2.64%
C: -4.18%
kio-101 publication treatment eye study
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases
Published: 2024-02-01 (Crawled : 15:30) - biospace.com/
KPRX | $0.502 -1.57% -1.59% 49K
|
Manufacturing
|
| O: 37.0%
H: 31.87%
C: 12.32%
kio-301 innovation treatment pharmaceuticals agreement
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
Published: 2024-02-01 (Crawled : 15:30) - biospace.com/
KPRX | $0.502 -1.57% -1.59% 49K
|
Manufacturing
|
| O: 37.0%
H: 31.87%
C: 12.32%
million pharmaceuticals
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa
Published: 2023-11-09 (Crawled : 21:00) - biospace.com/
KPRX | $0.502 -1.57% -1.59% 49K
|
Manufacturing
|
| O: 2.79%
H: 2.85%
C: 0.53%
kio-301 pharmaceuticals results study
AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa
Published: 2023-11-06 (Crawled : 18:00) - biospace.com/
KPRX | $0.502 -1.57% -1.59% 49K
|
Manufacturing
|
| O: 12.89%
H: 4.29%
C: -4.07%
Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference
Published: 2023-10-16 (Crawled : 17:00) - biospace.com/
KPRX | $0.502 -1.57% -1.59% 49K
|
Manufacturing
|
| O: -5.16%
H: 1.9%
C: -0.15%
conference pharmaceuticals
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
CLSD | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
14:00
CDZI P 25000 | $2.25 0.0% 260K
|
Utilities
|
14:00
ETST P 39000 | $0.068 -67.14% 43K
|
Manufacturing
|
13:30
FNLC P 1275 | $22.97 3.66% 3.53% 21K
|
Finance
|
12:30
ADMQ | $0.0532 -40.18% 480K
|
|
10:30
AXR P 2400 | $21.0 -5.28% 0.0% 13K
|
Finance
|
21:00
QCRH P 118 | $57.315 3.44% 3.32% 66K
|
Finance
|
18:01
VUZI P 7500 | $1.19 -5.56% -5.88% 550K
|
Electronic Technology
|
18:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10